Kardium Inc.
$816.9K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aesculap AG
Aesculap AG reported $815,790.58 across General Payments, Research, and Ownership to 24 physicians and teaching hospitals across 24 transactions.
- $815.8K Above-median payer
- All-tracks total
- 24 Below-median volume
- Transactions
- 24 Below-median reach
- Recipients
- −$30.2K
- General Payments vs PY2023
Aesculap AG reported $815,790.58 across all CMS Open Payments tracks (General + Research + Ownership) to 24 physicians and teaching hospitals in Program Year 2024 - ranking #667 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $815,790.58, averaging $34.0K per recipient.
Aesculap AG's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
12/100
Total payments
F
18/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aesculap-ag Aesculap AG
$815.8K · #667/1,925 · 0.0% industry · PY2024
- TOT $815.8K
- RANK #667
- SHARE 0.0%
- TXN 24
- RCP 24
- CAT 1
- GEN $815.8K
- ΔGEN −$30.2K
- TOP1 40.7%
- PY 2024
Volume peers
Nearest volume peer: Kardium Inc. ($816.9K)
Aesculap AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aesculap AG's CMS-reported General Payments decreased by $30.2K (−3.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AESCULAP AGPY2023: AESCULAP AGPY2024: Aesculap AG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $845,956.70
- PY2024
- $815,790.58
What the Data Shows for Aesculap AG
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Aesculap AG that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $815.8K, accounting for 100.0% of this company's General Payments and 24 transactions.
General Payment Breakdown by Type
Aesculap AG made 1 types of general payments. "Royalty or License" is the largest category at $815.8K, 100.0% of General Payments.
How Aesculap AG divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $815.8K | 24 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $815,790.58 (100.0%) of $815,790.58 in this company's General Payments records across 5 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aesculap AG
The five named recipients with the highest reported General Payments from this company
- 1
William Mihalko
$332,051.30 across 8 reported transactions
- 2
James Yue
$197,414.25 across 4 reported transactions
- 3
Rolando Garcia
$171,562.63 across 4 reported transactions
- 4
Khaled Saleh
$107,607.51 across 4 reported transactions
- 5
Sam Hakki
$7,154.89 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aesculap AG's spend rank (#667 of 1,925, top 35% by spend) and concentration rank (#586 of 1,838, top 32% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Renalytix AI, Inc. : $131.1K total payments, HHI 2909
- ImpediMed, Inc. : $128.1K total payments, HHI 2895
- NovApproach Spine, LLC : $88.4K total payments, HHI 2890
- Medyssey USA, Inc : $307.8K total payments, HHI 2888
- Vaporox, Inc. : $51.8K total payments, HHI 2887
- Alafair Biosciences, Inc. : $231.7K total payments, HHI 2862
- Aesculap AG (this company) : $815.8K total payments, HHI 2859
- Biocartis US, Inc : $9.2K total payments, HHI 2857
- US Endoscopy : $971.8K total payments, HHI 2854
- X4 Pharmaceuticals, Inc. : $80.9K total payments, HHI 2850
- Ultrasight Inc : $162.3K total payments, HHI 2847
- Steris Corporation : $514.3K total payments, HHI 2847
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aesculap AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aesculap AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aesculap AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
Central California Surgical Distributors, LLC
$814.0K 16 recipients
Compare payment profiles
Curonix LLC
$810.1K 6,645 recipients
Compare payment profiles
Spine Wave, Inc.
$825.7K 509 recipients
Compare payment profiles
Precision Spine, Inc.
$802.9K 291 recipients
Compare payment profiles
Next Science LLC
$829.9K 1,698 recipients
Compare payment profiles
Put this to use
Aesculap AG ranks #667 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Aesculap AG. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.